ArticleInternational journal of clinical oncology2026
Electronic patient-reported outcome monitoring and quality of life during later-line nivolumab therapy for advanced gastric cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHealth-related quality of life (HRQoL) often deteriorates during later-line treatment for advanced gastric cancer. Although nivolumab monotherapy has been an established treatment option in this setting, HRQoL data remain limited. This study aimed to examine associations between symptomatic adverse events (AEs) and HRQoL deterioration and to evaluate the feasibility of home-based electronic patient-reported outcome (ePRO) monitoring.
methodsThis prospective observational study enrolled patients aged ≥ 20 years with an ECOG performance status of 0-2 who were scheduled to receive later-line nivolumab monotherapy in clinical practice. Patients self-reported symptomatic AEs using PRO-CTCAE and assessed HRQoL weekly using FACT-Ga via a smartphone-based ePRO system for 12 weeks. The association between symptom deterioration and HRQoL decline was analyzed using a general linear model. Digital literacy and impressions of ePRO were also surveyed.
resultsAmong 29 evaluable patients, 20 completed the 12-week monitoring period. Median time to HRQoL deterioration was 9 weeks. Several symptomatic AEs, including stomatitis, dysgeusia, pain, malaise, and depression, showed nominal associations with HRQoL decline in unadjusted exploratory analyses (all nominal p < 0.05). Despite 37.9% of patients not regularly using smartphones, adherence to ePRO reporting was high, with only 0.95% missing data.
conclusionsExploratory analyses suggested potential associations between specific symptomatic AEs and HRQoL deterioration during later-line nivolumab therapy for advanced gastric cancer. ePRO monitoring achieved high data completeness, although patient acceptability was limited. These findings support further evaluation of ePRO as a tool for timely symptom recognition, alongside strategies to improve acceptability.
Indexed as
Identifiers
42905383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.